The Pharma Data

AUGUST 15, 2021

inhibitor, for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery. months (range, 2.8 as assessed by IRC.

Treatment 52

Treatment Disease Clinical Trials Therapies 52

The Pharma Data

MARCH 8, 2021

At a time where there is unmet need for antiviral treatments against SARS-CoV-2, we are encouraged by these preliminary data.”. Molnupiravir has been shown to be active in several models of SARS-CoV-2, including for prophylaxis, treatment, and prevention of transmission, as well as SARS-CoV-1 and MERS. About Molnupiravir.

Trials 69

Trials Virus RNA Research Laboratories 69

Conversations in Drug Development Trends

DECEMBER 12, 2022

This enables us to recruit patients ​quickly​​ ​and pinpoint optimal study locations to help our sponsors uncover new and potentially lifesaving treatments for people suffering from rare diseases. What is the difference between a Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory vs a research laboratory?

Clinical Trials 52

Clinical Trials Trials Laboratories Research Laboratories 52

The Pharma Data

JANUARY 21, 2021

It is not currently authorized for use as a preventative treatment in nursing homes, but Eli Lilly said it intends to work with regulators to try and get the clearances expanded. James Miessler. Source link.

Nurses 52

Nurses Research Laboratories Laboratories Virus 52

The Pharma Data

SEPTEMBER 21, 2020

However, the combo treatment performed better in certain cancers compared to others, reporting a response in 32.3% In another phase II trial, Keytruda plus Lenvima demonstrated an ORR between 9.7-32.3% of highly-treated ovarian cancer patients and 29% of previously treated TNBC patients. Source link.

Research Laboratories 52

Research Laboratories Laboratories Trials Therapies 52

Drug Target Review

NOVEMBER 1, 2023

I work in the Centre for Cancer Drug Discovery (CCDD) at The Institute of Cancer Research in London, which is an academic drug discovery centre. The mission of the CCDD is to discover novel small-molecule therapeutics for the treatment of cancer and progress them to hypothesis testing phase 1 clinical trials.

Fragment Screening 96

Fragment Screening Biochemical Assays Small Molecule Biophysical Assays 96

The Pharma Data

JULY 12, 2021

It continues to be critically important to advance potential antiviral treatments to address the devastating impact of COVID-19 globally,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. “If View the full release here: [link]. “It

Clinical Trials 52

Clinical Trials Laboratories Research Laboratories RNA 52

KIF1A

MAY 24, 2023

The approach often focuses the patient-voice around a common goal of treatment, be it to inform a clinical endpoint or identify patient demographics for a drug treatment. The story of how we became connected with Dr. Shi is a shining example of the KIF1A Research Network in action. So, let’s plant the seeds early.

Disease 98

Disease Laboratories Research Science 98

The Pharma Data

JUNE 2, 2023

Food and Drug Administration (FDA) for the treatment of adult patients with deleterious or suspected deleterious BRCA -mutated ( BRCA m) metastatic castration-resistant prostate cancer (mCRPC). We look forward to bringing the benefit of this LYNPARZA combination to patients earlier in their treatment.” In the U.S.,

FDA Approval 52

FDA Approval FDA Therapies Treatment 52

The Pharma Data

MARCH 16, 2021

Head of Department CNS Diseases Research at Boehringer Ingelheim. “By By combining our expertise, we hope to make significant steps forward to finding solutions for patients for which there currently is no treatment.”. Hugh Marston, Ph.D., The Lieber Institute for Brain Development.

Licensing 52

Licensing Licensing Research Laboratories Treatment 52

PerkinElmer

MAY 28, 2020

As viruses evolve over time, new, agile research applications need to be created to combat these evasive intruders from exploiting host cells. Unfortunately, the road towards treatment can be time-consuming, especially when utilizing assays with live virus.

Vaccine 52

Vaccine Disease Virus Small Molecule 52

The Pharma Data

MARCH 30, 2021

In Europe, KEYTRUDA is approved for the treatment of adult patients with advanced or metastatic urothelial carcinoma (bladder cancer) who are not eligible for cisplatin-containing chemotherapy and whose tumors express PD-L1 with a Combined Positive Score (CPS) ? About KEYTRUDA ® (pembrolizumab) Injection, 100 mg. Non-Small Cell Lung Cancer.

FDA Approval 52

FDA Approval Treatment FDA Therapies 52

The Pharma Data

JULY 29, 2021

About Kumquat Biosciences Kumquat Biosciences is a privately held drug discovery and development company committed to creating breakthrough medicines for the treatment of cancer. There will be no change to Lilly’s 2021 non-GAAP earnings per share guidance as a result of this transaction.

Small Molecule 52

Small Molecule Immune Response Research Laboratories Laboratories 52

The Pharma Data

JULY 12, 2021

Joan Butterton, vice president, Global Clinical Development, Infectious Diseases, Merck Research Laboratories. “We We believe that islatravir has the potential to serve as the foundation of future treatment and prevention regimens, and we look forward to sharing new data from our HIV portfolio and pipeline.”. Abstract 2361.

Pharmacokinetics 52

Pharmacokinetics Clinical Trials Trials Treatment 52

The Pharma Data

OCTOBER 12, 2021

The Award recognizes the research that has the highest translational potential Translational medicine is an interdisciplinary branch in the biomedical field that aims to combine benchside, bedside and community to promote enhancement in prevention, diagnosis, and treatment. This year, Prof.

Research Laboratories 52

Research Laboratories Laboratories Therapies Production 52

The Pharma Data

MARCH 5, 2021

” “While covalent BTK inhibitors and venetoclax have transformed the treatment of CLL, we now see many patients needing new therapeutic alternatives,” said Brian Koffman, MDCM (retired), chief medical officer of the CLL Society. chief medical officer of Loxo Oncology at Lilly. About Loxo Oncology at Lilly.

Clinical Trials 52

Clinical Trials Pharmacokinetics Trials Therapies 52

The Pharma Data

JUNE 1, 2022

Anderson has led the team of infectious disease biologists that validated and delivered to an emergency use authorization PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets), Pfizer’s novel COVID-19 oral treatment. Dr. Anderson joined Pfizer via Wyeth in 2007.

Vaccine 40

Vaccine Research Laboratories Doctors 40

The Pharma Data

MARCH 13, 2021

Lilly’s chief scientific officer and president of Lilly Research Laboratories. Donanemab has the potential to become a very important treatment for Alzheimer’s disease. As early as nine months (36 weeks) after initiation of treatment, a significant difference in decline by iADRS was observed.

Disease 40

Disease Trials Treatment Medical Schools 40

The Pharma Data

APRIL 11, 2021

The data were presented at the 2021 American Association for Cancer Research (AACR) Annual Meeting, held virtually April 10-15, 2021. In this cohort, the most common treatment-emergent adverse events of any grade (?20%) No patients in this cohort discontinued treatment due to treatment-related adverse events.

Research 52

Research Treatment Therapies Trials 52

NIH Director's Blog: Drug Development

MARCH 11, 2014

Credit: Jane Ades, National Human Genome Research Institute, NIH Type 2 diabetes (T2D) tends to run in families, and over the last five years the application of genomic technologies has led to discovery of more than 60 specific DNA variants that contribute to risk.

DNA 52

DNA Drugs Disease Research Laboratories 52

The Pharma Data

DECEMBER 17, 2020

Most recently, Cadavid served as senior vice president and Head of Clinical Development at Fulcrum Therapeutics where he led the development of multiple small molecules for the treatment of genetically defined rare diseases. Previously, Mohindru was CFO and CSO of Cara Therapeutics. Earlier, she served as CSO at Curis, Inc.

Small Molecule 52

Small Molecule Clinical Development Engineering Pharmaceuticals 52

PPD

OCTOBER 12, 2023

These treatments use a vector to introduce the desired nucleic acid code to replace or modify protein expression or use cells to alter/restore a specific cell type. Cell and gene therapies (CGTs) are one of the fastest growing areas in human therapeutics.

Laboratories 52

Laboratories Clinical Trials Protein Expression Pharmacokinetics 52

The Pharma Data

SEPTEMBER 17, 2020

Lilly is currently studying several potential neutralizing antibodies for the prevention and/or treatment of COVID-19 as either monotherapy or in combination. Lilly ‘s chief scientific officer and president of Lilly Research Laboratories. Lilly ‘s chief scientific officer and president of Lilly Research Laboratories.

Therapies 52

Therapies Production Government Disease 52

The Pharma Data

NOVEMBER 18, 2021

A review by the external Data Monitoring Committee (eDMC) determined that this effect was related to treatment with the combination of ISL08507; the greatest decreases were seen in the arms of the study receiving the highest doses of MK-8507 (200 mg and 400 mg). The company has notified investigators and paused development of MK-8507.

Clinical Trials 52

Clinical Trials Treatment Trials RNA 52

The Pharma Data

MARCH 23, 2021

First Anti-PD-1 in Combination With Chemotherapy Approved for the First-Line Treatment of Esophageal and GEJ Carcinoma, Regardless of Histology or PD-L1 Expression. We are committed to putting patients first and continuing our research to help advance new approaches to potentially extend the lives of people with cancer.

Treatment 52

Treatment FDA Approval FDA Therapies 52

The Pharma Data

OCTOBER 25, 2021

Doravirine is approved for the treatment of grown-ups with HIV-1 in combination with other antiretrovirals, as a single agent (PIFELTRO) and a element of a single- tablet authority (DELSTRIGO; DOR/ 3TC/ TDF). Merck Research Laboratories. “ See Named Safety Information below. Named Safety Information about PIFELTRO and DELSTRIGO.

Treatment 52

Treatment Trials RNA Clinical Trials 52

The Pharma Data

OCTOBER 27, 2021

– This Clinical Study is the First from Merck and Gilead’s Collaboration to Develop Potential Long-Acting HIV Treatment Options –. Joan Butterton, vice chairman, global clinical development, contagious conditions, Merck Research Laboratories. There’s presently no cure for HIV or AIDS.

Treatment 52

Treatment Clinical Trials Clinical Development Trials 52

Alta Sciences

APRIL 4, 2025

Getting to the Heart of Science: How Clinical Research Saved My Life and Continues to Inspire Me pmjackson Fri, 04/04/2025 - 18:01 By Josiah Liang, Research Laboratory Technician, Clinical Diagnostic and Central Laboratory Services. How Clinical Research Saved My Life I was born in 2000.

Clinical Research 52

Clinical Research Science Research Research Laboratories 52

The Pharma Data

JULY 6, 2021

accelerated approval indication for KEYTRUDA for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 [combined positive score (CPS ? About KEYTRUDA ® (pembrolizumab) Injection, 100 mg.

FDA Approval 52

FDA Approval FDA Treatment Therapies 52

The Pharma Data

SEPTEMBER 21, 2020

AstraZeneca and MSD’s Lynparza (olaparib) has been recommended for marketing authorisation across the European Union for the first-line maintenance treatment with bevacizumab for patients with homologous recombination deficient (HRD)-positive advanced ovarian cancer. Photo by D Wells. Conor Kavanagh. Source link.

Research Laboratories 52

Research Laboratories Treatment Trials Laboratories 52

The Pharma Data

JULY 8, 2021

KEYTRUDA Is Now Approved for the Treatment of Patients With Recurrent or Metastatic or Locally Advanced cSCC That Is Not Curable by Surgery or Radiation. There are currently more than 1,500 trials studying KEYTRUDA across a wide variety of cancers and treatment settings. KENILWORTH, N.J.–(BUSINESS

FDA Approval 52

FDA Approval FDA Treatment Therapies 52

Drug Target Review

AUGUST 28, 2024

What are the main challenges currently faced in the treatment of chronic liver diseases, and how does Resolution Therapeutics aim to address these challenges? Dr Brass has published over 85 peer reviewed articles and more than 200 abstracts, primarily in the field of hepatology, in both the areas of clinical and basic science research.

Therapies 116

Therapies Disease Engineering Medical Schools 116

The Pharma Data

APRIL 8, 2021

Since its first approval in renal cell carcinoma nearly two years ago, KEYTRUDA has become an important first-line treatment option in combination with axitinib for patients with advanced renal cell carcinoma,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories.

Therapies 52

Therapies Disease Treatment Research Laboratories 52

The Pharma Data

AUGUST 30, 2021

KEYTRUDA Now Approved for the Treatment of Patients With PD-L1-Positive, Hormone Receptor-Negative and HER2-Negative, Inoperable or Recurrent Breast Cancer. KEYTRUDA Also Approved for the Treatment of Patients With Unresectable, Advanced or Recurrent High Microsatellite Instability (MSI-H) Colorectal Cancer. months [95% CI, 5.4-32.4]

Treatment 52

Treatment Trials Research Laboratories Clinical Trials 52

The Pharma Data

NOVEMBER 22, 2020

The FDA granted Breakthrough Therapy Designation to the drug for RET fusion-positive NSCLC that has progressed after platinum-based chemotherapy, and RET mutation-positive MTC that requires systemic treatment and for which there are no alternative treatments. It holds the rights for the drug in the rest of the world.

FDA 52

FDA Licensing Licensing Treatment 52

The Pharma Data

MARCH 16, 2021

inhibitor belzutifan (pronounced bell-ZOO-ti-fan), a novel investigational candidate in Merck’s oncology pipeline, for the potential treatment of patients with von Hippel-Lindau (VHL) disease-associated renal cell carcinoma (RCC), not requiring immediate surgery. in patients with VHL disease-associated RCC. “Von

FDA 52

FDA Disease Trials Drugs 52

The Pharma Data

AUGUST 10, 2021

The FDA’s acceptance of our application adds to our momentum of advancing new treatment options to address the most challenging cancers facing women,” said Dr. Scot Ebbinghaus, vice president, clinical research, Merck Research Laboratories. Source link: [link].

FDA 52

FDA Therapies Treatment Clinical Research 52